{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-006628","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2022-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.384483+00:00","generated_at":"2026-06-26T01:52:20.242380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tactile Medical Q1 revenue $48.0M (+12% YoY); net loss $15.6M vs $2.3M loss YoY","bullets":["Revenue $48.0M (+12% YoY); net loss $15.6M ($0.78 diluted EPS) vs $2.3M ($0.12) in Q1 2021.","Operating loss $14.9M vs $4.1M YoY; non-GAAP operating loss $5.4M vs $3.1M.","Adjusted EBITDA loss $2.6M vs $7K loss YoY.","Reaffirmed FY2022 revenue guidance $235M-$240M (13-15% growth).","Airway clearance product line contributed $7.3M revenue; lymphedema product line declined 5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-006628","json":"https://secwatch.observer/filing/0001558370-22-006628.json","markdown":"https://secwatch.observer/filing/0001558370-22-006628.md","text":"https://secwatch.observer/filing/0001558370-22-006628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837022006628/0001558370-22-006628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837022006628/tcmd-20220502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:52:20.242380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}